Table 3.
The Performance of ΔCpPAX1 in predicting CIN2 upgrade to CIN3, and CIN3 upgrade to ESCC after conization.
| Test | Sensitivity % (95%CI) |
Specificity % (95%CI) |
PPV % (95%CI) |
NPV % (95%CI) |
OR (95%CI) |
|---|---|---|---|---|---|
| CIN2CDB (n = 100) | |||||
| CIN3+CKC (n = 36) | |||||
| △CpPAX1 ≤ 10.83 | 44.4 (27.9-61.9) | 82.8 (71.3-91.1) | 59.3 (43.2-73.6) | 72.6 (65.9-78.4) | 3.86 (1.53-9.71) |
| Cytology (ASCUS+) | 44.4 (27.7-61.9) | 45.3 (32.8-58.3) | 31.4 (22.9-41.2) | 59.2 (49.3-68.3) | 0.66 (0.29-1.51) |
| hrHPV (+) | 97.2 (85.5-99.9) | 9.4 (3.5-19.3) | 37.6 (35.4-39.9) | 85.7 (42.9-98.0) | 3.62 (0.42-31.34) |
| CIN3CDB (n = 118) | |||||
| ESCCCKC (n = 23) | |||||
| △CpPAX1 ≤ 6.36 | 78.3 (56.3-92.6) | 84.2 (75.3-90.9) | 54.5 (41.8-66.7) | 94.1 (88.0-97.2) | 19.20 (6.18-59.67) |
| Cytology ≥ LSIL | 78.3 (56.3-92.5) | 58.9 (48.4-68.9) | 31.6 (25.0-38.9) | 91.8 (83.5-96.1) | 5.17 (1.77-15.10) |
| HPV16/18 (+) | 73.9 (51.6-89.8) | 46.3 (36.0-56.8) | 25.0 (19.7-31.2) | 88.0 (78.1-93.8) | 2.44 (0.89-6.74) |
Estimated sensitivity and specificity of PAX1m at maximum value of Youden index.